Core Viewpoint - Becton Dickinson and Company (BD) has reduced its fiscal year 2026 profit outlook due to the spin-off of its biosciences & diagnostic solutions business, resulting in a 3% decline in its share price [1][2]. Financial Outlook - BD expects FY26 earnings per share (EPS) to be in the range of $12.35 to $12.65, a decrease from the previous estimate of $14.75 to $15.05 [2]. - The company's market capitalization stands at $59.09 billion following the announcement [2]. Q1 FY2026 Performance - BD reported Q1 FY2026 profits of $5.25 billion, reflecting a 1.6% increase compared to Q1 FY2025 [3]. - The medical essentials segment generated $1.60 billion, marking the weakest growth at 0.6% [3]. - Interventional and connected care segments performed well, generating $1.33 billion and $1.13 billion, respectively [3]. Growth Segments - The interventional segment showed the highest growth at 5.8%, followed by connected care at 5.5% and biopharma systems at 2.7% [4]. - CEO Tom Polen emphasized the strong Q1 performance as a result of disciplined execution and broad-based growth across key markets [4]. Strategic Developments - The completion of the transaction with Waters is seen as a significant milestone in BD's strategy to enhance shareholder value, marking a transition to "New BD" [4].